Raymond James Financial
FBLG icon

Raymond James Financial’s FibroBiologics FBLG Stock Holding History

Raymond James Financial’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-932
Closed -$4.19K – 5471
2025
Q4 		$4.19K Hold
932
– – ﹤0.01% 5151
2025
Q3 		$10.2K Hold
932
– – ﹤0.01% 4937
2025
Q2 		$11.6K Hold
932
– – ﹤0.01% 5862
2025
Q1 		$16.8K Hold
932
– – ﹤0.01% 4732
2024
Q4 		$37.3K Buy
+932
New +$50K ﹤0.01% 4647

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Raymond James Financial's FBLG Position: Q1 2026 in Review

Raymond James Financial sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 932 shares — an estimated $4.19K sold.

Raymond James Financial first reported a position in FBLG in Q4 2024 and held it in 5 quarters. The position peaked at $37.3K in Q4 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Raymond James Financial reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 932 FibroBiologics shares in Q1 2026, an estimated $4.19K.
  • Raymond James Financial first reported a position in FibroBiologics in Q4 2024 and held it in 5 quarters.
  • Raymond James Financial's FibroBiologics position peaked at $37.3K in Q4 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.